cropped-SMP.png
Directrice

Parcours

Brief Biography

Medical doctor specialized in biology (1993). After an MSc (Institut Pasteur, Paris) and a post-doctoral fellowship in transfusion (National Blood center, LR Salmi, in the environmental team at the University of Bordeaux), I gained her PhD in Epidemiology (2002). I obtained the French authorization to supervise research (HDR, University of Bordeaux) in 2006 and became a professor in Epidemiology in 2010. I head the cancer axis in the Inserm U897 unit since 2010 and the epidemiological axis in SIRIC Brio since 2012. I have published more than 100 articles and authored 9 book chapters.

Research Interests

Focus on assessing disparities in cancer outcomes (recurrence, survival) and predicting events in cancer through epidemiological studies (population-based studies, prognostic models, diagnostic tools). I’m responsible for the design and analysis of several clinical trials (drug, medical devices and public health interventions) and cohort studies (breast, colorectal cancer and sarcoma). I collaborate with geriatricians and oncologists on a number of projects focusing on elderly patients with cancer.

 

Fonctions

MD, PhD
PUPH section 4601 Epidemiologie, Economie de la santé et Prévention
Responsable de l’axe cancer, U897 Université Bordeaux
Coordonnateur du département de recherche clinique et Information médicale , CLCC Bergonié / Bordeaux

 Publications

Exemples de publications entre 2011 et 2015

1: Mazroui Y, Mauguen A, Mathoulin-Pélissier S, MacGrogan G, Brouste V, Rondeau V. Time-varying coefficients in a multivariate frailty model: Application to breast cancer recurrences of several types and death. Lifetime Data Anal. 2015 May 6. 

2: Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A’Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S,  Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breastcancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol. 2015 May;26(5):873-879.

3: Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M,Litière S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F,Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R,Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V,Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S,Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S. Guidelines fortime-to-event end point definitions in sarcomas and gastrointestinal stromaltumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol. 2015May;26(5):865-872.

4: Mauguen A, Rachet B, Mathoulin-Pélissier S, Lawrence GM, Siesling S, MacGrogan G, Laurent A, Rondeau V. Validation of death prediction after breast cancer relapses using joint models. BMC Med Res Methodol. 2015 Apr 1;15(1):27. 

5: Tunon-de-Lara C, Chauvet MP, Baranzelli MC, Baron M, Piquenot J, Le-Bouédec G, Penault-Llorca F, Garbay JR, Blanchot J, Mollard J, Maisongrosse V,Mathoulin-Pélissier S, MacGrogan G. The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated byMastectomy: The Cinnamome Prospective Multicenter Study. Ann Surg Oncol. 2015 Mar17. 

6: Doussau A, Thiébaut R, Geoerger B, Schöffski P, Floquet A, Le Deley MC, Mathoulin-Pélissier S, Rizzo E, Fumoleau P, Le Tourneau C, Paoletti X. A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials. Ann Oncol. 2015 Feb;26(2):422-8. 

7: Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E,

Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J,Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A,

Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. Guidelines for time-to-event end-pointdefinitions in trials for pancreatic cancer. Results of the DATECAN initiative(Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur J Cancer. 2014 Nov;50(17):2983-93. 

8: Coureau G, Bouvier G, Lebailly P, Fabbro-Peray P, Gruber A, Leffondre K, Guillamo JS, Loiseau H, Mathoulin-Pélissier S, Salamon R, Baldi I. Mobile phone use and brain tumours in the CERENAT case-control study. Occup Environ Med. 2014  Jul;71(7):514-22. 

9: Grellety T, Petit-Monéger A, Diallo A, Mathoulin-Pelissier S, Italiano A. Quality of reporting of phase II trials: a focus on highly ranked oncology journals. Ann Oncol. 2014 Feb;25(2):536-41. 

10: Mathoulin-Pélissier S, Chevreau C, Bellera C, Bauvin E, Savès M, Grosclaude P, Albert S, Goddard J, Le Guellec S, Delannes M, Bui BN, Mendiboure J, Stoeckle E, Coindre JM, Kantor G, Kind M, Cowppli-Bony A, Hoppe S, Italiano A. Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study. Ann Oncol. 2014 Jan;25(1):225-31. 

11: Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, Albrand G,Servent V, Jean OS, van Praagh I, Kurtz JE, Périn S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Mathoulin-Pélissier S, Rainfray M. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective MulticenterCohort Study. PLoS One. 2014 Dec 11;9(12):e115060. .

12: Evrard S, Poston G, Kissmeyer-Nielsen P, Diallo A, Desolneux G, Brouste V,Lalet C, Mortensen F, Stättner S, Fenwick S, Malik H, Konstantinidis I, DeMatteo  R, D’Angelica M, Allen P, Jarnagin W, Mathoulin-Pelissier S, Fong Y. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One. 2014 Dec 8;9(12):e114404. 

13: Mauguen A, Rachet B, Mathoulin-Pélissier S, MacGrogan G, Laurent A, Rondeau V. Dynamic prediction of risk of death using history of cancer recurrences in joint frailty models. Stat Med. 2013 Dec 30;32(30):5366-80.

14: Mazroui Y, Mathoulin-Pélissier S, Macgrogan G, Brouste V, Rondeau V. Multivariate frailty models for two types of recurrent events with a dependent terminal event: application to breast cancer data. Biom J. 2013 Nov;55(6):866-84.

15: Bellera C, Praud D, Petit-Monéger A, McKelvie-Sebileau P, Soubeyran P, Mathoulin-Pélissier S. Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin’s lymphoma: a systematic review. Cancer Treat Rev. 2013 Nov;39(7):812-7. 

16: Hoppe S, Rainfray M, Fonck M, Hoppenreys L, Blanc JF, Ceccaldi J, Mertens C, Blanc-Bisson C, Imbert Y, Cany L, Vogt L, Dauba J, Houédé N, Bellera CA, Floquet A, Fabry MN, Ravaud A, Chakiba C, Mathoulin-Pélissier S, Soubeyran P. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol. 2013 Nov 1;31(31):3877-82.

17: Rondeau V, Schaffner E, Corbière F, Gonzalez JR, Mathoulin-Pélissier S. Cure frailty models for survival data: application to recurrences for breast cancer and to hospital readmissions for colorectal cancer. Stat Methods Med Res. 2013 Jun;22(3):243-60. 

18: Bellera CA, Pulido M, Gourgou S, Collette L, Doussau A, Kramar A, Dabakuyo TS, Ouali M, Auperin A, Filleron T, Fortpied C, Le Tourneau C, Paoletti X, Mauer  M, Mathoulin-Pélissier S, Bonnetain F. Protocol of the Definition for theAssessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal  consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials. Eur J Cancer. 2013Mar;49(4):769-81.

19: Mathoulin-Pélissier S, Bellera C, Rainfray M, Soubeyran P. Screening methods for geriatric frailty. Lancet Oncol. 2013 Jan;14(1):e1-2. 

20: Delva F, Soubeyran P, Rainfray M, Mathoulin-Pélissier S. Referral of elderly cancer patients to specialists: action proposals for general practitioners. Cancer Treat Rev. 2012 Nov;38(7):935-41.

21: Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, Soubeyran PL. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012 Aug;23(8):2166-72. 

22: Mathoulin-Pélissier S, Bécouarn Y, Belleannée G, Pinon E, Jaffré A, Coureau G, Auby D, Renaud-Salis JL, Rullier E; Regional Aquitaine Group for Colorectal cancer GRACCOR. Quality indicators for colorectal cancer surgery and care according to patient-, tumor-, and hospital-related factors. BMC Cancer. 2012 Jul 19;12:297. 

23: Mazroui Y, Mathoulin-Pelissier S, Soubeyran P, Rondeau V. General joint frailty model for recurrent event data with a dependent terminal event: Application to follicular lymphoma data. Stat Med. 2012 May 20;31(11-12):1162-76.

24: Bui-Nguyen B, Ray-Coquard I, Chevreau C, Penel N, Bay JO, Coindre JM, Cupissol D, Italiano A, Bonichon F, Lotz JP, Thyss A, Jimenez M, Mathoulin-Pélissier S, Blay JY; GSF-GETO French Sarcoma Group. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol. 2012 Mar;23(3):777-84. 

25: Penel N, Glabbeke MV, Mathoulin-Pelissier S, Judson I, Sleijfer S, Bui B,Schoffski P, Ouali M, Marreaud S, Brouste V, Duhamel A, Hohenberger P, Blay JY.Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. Br J Cancer. 2011 May 10;104(10):1544-50. 

26: Toulmonde M, Bellera C, Mathoulin-Pelissier S, Debled M, Bui B, Italiano A. Quality of randomized controlled trials reporting in the treatment of sarcomas. JClin Oncol. 2011 Mar 20;29(9):1204-9. 

27: Lebeau M, Mathoulin-Pélissier S, Bellera C, Tunon-de-Lara C, Daban A,Lipinski F, Jaubert D, Ingrand P, Migeot V; REPERES Group. Breast cancer care compared with clinical Guidelines: an observational study in France. BMC Public Health. 2011 Jan 20;11:45.

28: Delva F, Marien E, Fonck M, Rainfray M, Demeaux JL, Moreaud P, Soubeyran P,Sasco AJ, Mathoulin-Pélissier S. Factors influencing general practitioners in thereferral of elderly cancer patients. BMC Cancer. 2011 

partenaires

logo_ISPED logo_SFR-santepublique-societe logo_CHU-Bordeaux logo_Institut-Bergonie logo_INRIA logo_ANRS logo_HONcode